Elraglusib

Elraglusib is an inhibitor of GSK-3 used in studies of PI3K-Akt-mTOR Signaling and Wnt Signaling and related signaling programs. It is especially relevant in apoptosis, cancer, and cell cycle models, where defined compound exposure can be linked to growth-factor signaling, survival control, and nutrient-sensing outputs and beta-catenin-dependent transcription and developmental signaling.

By inhibiting GSK-3, Elraglusib can be used to examine growth-factor signaling, survival control, and nutrient-sensing outputs and beta-catenin-dependent transcription and developmental signaling. The kinase annotation adds relevance to biochemical kinase assays, phospho-signaling studies, and selectivity profiling, together with downstream-response mapping in the same experimental setting. In apoptosis, cancer, and cell cycle models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.

Research Applications

• Target-focused assays involving GSK-3
• Pathway perturbation studies connected to PI3K-Akt-mTOR Signaling and Wnt Signaling and related signaling programs
• Concentration-response inhibition and target-dependence studies
• Biochemical kinase assays, phospho-signaling studies, and selectivity profiling

Overall, Elraglusib is appropriate when a defined chemical perturbant is needed to connect GSK-3 with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in apoptosis, cancer, and cell cycle models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.